| Price | 0.15 |
| Price Change Today | +$0.03 (+25.00%) |
| P&P rating | ![]() |
| Zacks Rank | N/A - N/A |
| Open Price | $0.14 |
| Previous Close | $0.12 |
| Daily Range | $0.14 - $0.15 |
| 52-Week Range | $0.12 - $0.35 |
| Volume | 12,400 |
| Progen Pharmaceuticals Limited is an Australian-based globally focused biotechnology company committed to the discovery, development and commercialisation of small molecule therapeutics primarily for the treatment of cancer. The company has an intimate understanding of the role of heparan sulfate, a complex sugar, in cancer disease processes and have developed a small-molecule drug development program in this area. PI-88 is the first product produced from this research and promising signs of efficacy in humans are emerging from the clinical program. A Phase II clinical trial program across multiple cancers is currently underway. Areas of investigation include lung cancer, primary liver cancer, multiple myeloma and melanoma and prostate cancer. This is supplemented by an innovative drug discovery program that intends to funnel future compounds through the pipeline and into human trials. | |




Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment